Evidence map›Paper›PMID 40042775›Full record

ArticleAnnals of nuclear medicine2025

Differentiating second primary lung cancer from pulmonary metastasis in patients of single solitary pulmonary lesion with extrapulmonary tumor using multiparametric analysis of FDG PET/CT.

Honghong Liu, Xiaolin Meng, Guanyun Wang, Shulin Yao, Yanmei Wang, Ruimin Wang, Tao Wang

Abstract read
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Honghong Liu *Departments of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Beijing, 100853, China.
Xiaolin Meng *Departments of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Beijing, 100853, China.
Guanyun WangDepartment of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
Shulin YaoDepartments of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Beijing, 100853, China.
Yanmei WangGE Healthcare China, Pudong New Town, Shanghai, 200125, China.
Ruimin WangDepartments of Nuclear Medicine, the First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Beijing, 100853, China. NM_301@163.com.
Tao WangDepartments of Thoracic Surgery, the First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Beijing, 100853, China. doctorwt@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveUsing fluorine-18-fluorodeoxyglucose (

methodsThis study retrospectively studied 84 patients with preoperative exams utilizing

resultsThe highest discriminative diagnostic value was obtained by the independent parameters energy (1,039,358.1 [95126.2-1,965,032.2] vs. 92,011.0 [45916.3-365,322.9], P = 0.001). In comparison to peak standardized uptake value (SUVpeak), total lesion glycolysis (TLG), energy, lobulation, and spiculation alone, the combined model (addition of these factors) significantly improved the differential diagnostic efficacy of SPLCs and PMs (sensitivity = 76.2%, specificity = 83.8%, area under the curve [AUC] = 0.826) and permitted reclassification using IDI = 0.176 (P < 0.001), 0.169 (P < 0.001), 0.127 (P < 0.001), and categorical NRI = 0.678 (P < 0.001), 0.637 (P < 0.001), and 0.592 (P < 0.001) compared to SUVpeak, TLG and energy separately. DeLong's test revealed a statistically significant enhancement in ROC when compared to SUVpeak (Z = 2.372, P = 0.018), TLG (Z = 2.095, P = 0.036), and energy (Z = 2.318, P = 0.020).

conclusionCombining multiple parameters using

Indexed as

Fluorodeoxyglucose F18Lung NeoplasmsNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRetrospective StudiesROC CurveFluorodeoxyglucose F18MultiparameterPositron emission tomography/computed tomography (PET/CT)Pulmonary metastasis (PM)RadiomicsSecond primary lung cancer (SPLC)

Identifiers

PMID40042775
PMCPMC12095392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.